First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body
We're delighted to announce that the first patient of the NILK-2401 Phase I study, has been treated at START Madrid – FJD.
NILK-2401 is a novel κλ body-based CEACAM5-targeting CD47 (CEACAM5xCD47 bispecific antibody) for the immunotherapy of CEACAM5-expressing cancers.
Light Chain Bioscience | Novimmune SA, in partnership with LamKap Bio Group, is driving the clinical development of this innovative therapy in collaboration with four leading clinical hospitals highly experienced in early clinical development and immunotherapy of cancer, START Madrid – FJD led by Dr Victor Moreno, Vall d'Hebron Institute of Oncology (VHIO) led by Prof Josep Tabernero, Universidad de Navarra led by Prof Ignacio Melero and Dr Mariano Ponz, and Hospital 12 de Octubre led by Jon Zugazagoitia.
It is privilege to contribute to improving the lives of solid cancer patients. A heartfelt thank you to the patients and their families for entrusting us with their care.
If you're interested in learning more about NILK-2401, check out the manuscript detailing its development and characterization here: Frontiers in Immunology.
8th, October 2024
